MX2020001776A - Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. - Google Patents

Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.

Info

Publication number
MX2020001776A
MX2020001776A MX2020001776A MX2020001776A MX2020001776A MX 2020001776 A MX2020001776 A MX 2020001776A MX 2020001776 A MX2020001776 A MX 2020001776A MX 2020001776 A MX2020001776 A MX 2020001776A MX 2020001776 A MX2020001776 A MX 2020001776A
Authority
MX
Mexico
Prior art keywords
sub
sup
sulfonylthioureas
nlrp
sulfonylureas
Prior art date
Application number
MX2020001776A
Other languages
English (en)
Inventor
Miller David
Shannon Jonathan
Macleod Angus
Thom Stephen
St-Gallay Stephen
Alanine Thomas
Onions Stuart
Strutt Ian
Cooper Matthew
Carrillo Arregui Jokin
Original Assignee
Inflazome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713082.4A external-priority patent/GB201713082D0/en
Priority claimed from GBGB1718563.8A external-priority patent/GB201718563D0/en
Priority claimed from GBGB1721731.6A external-priority patent/GB201721731D0/en
Priority claimed from GBGB1721726.6A external-priority patent/GB201721726D0/en
Priority claimed from GBGB1810983.5A external-priority patent/GB201810983D0/en
Application filed by Inflazome Ltd filed Critical Inflazome Ltd
Publication of MX2020001776A publication Critical patent/MX2020001776A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención hace referencia a sulfonilureas y sulfonilureas que comprenden un anillo heteroarilo que contiene nitrógeno de 5 miembros unido al grupo sulfonilo, en donde el anillo heteroarilo se sustituye con un grupo R1 que contiene nitrógeno, en donde R1 contiene de 1 a 7 átomos diferentes de hidrógeno o halógeno. La presente invención también hace referencia a sales, solvatos y profármacos de dichos compuestos, a composiciones farmacéuticas de dichos compuestos y al uso de dichos compuestos en el tratamiento y prevención de trastornos médicos y enfermedades, especialmente mediante la inhibición de NLRP3.
MX2020001776A 2017-08-15 2018-08-15 Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. MX2020001776A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1713082.4A GB201713082D0 (en) 2017-08-15 2017-08-15 Novel compounds
GBGB1718563.8A GB201718563D0 (en) 2017-11-09 2017-11-09 Novel compounds
GBGB1721731.6A GB201721731D0 (en) 2017-12-22 2017-12-22 Novel compounds
GBGB1721726.6A GB201721726D0 (en) 2017-12-22 2017-12-22 Novel compounds
GBGB1810983.5A GB201810983D0 (en) 2018-07-04 2018-07-04 Novel compounds
PCT/EP2018/072119 WO2019034690A1 (en) 2017-08-15 2018-08-15 SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3

Publications (1)

Publication Number Publication Date
MX2020001776A true MX2020001776A (es) 2020-03-24

Family

ID=63364050

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001776A MX2020001776A (es) 2017-08-15 2018-08-15 Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.

Country Status (18)

Country Link
US (2) US11613542B2 (es)
EP (2) EP3668599A1 (es)
JP (1) JP2020531453A (es)
KR (1) KR20200041919A (es)
CN (2) CN111093773A (es)
AU (1) AU2018317798A1 (es)
BR (1) BR112020003014A2 (es)
CA (1) CA3071150A1 (es)
CL (1) CL2020000367A1 (es)
IL (1) IL272557A (es)
MA (1) MA49903A (es)
MX (1) MX2020001776A (es)
PE (1) PE20200758A1 (es)
RU (1) RU2020110219A (es)
SG (1) SG11202001166RA (es)
TW (1) TW201910316A (es)
UY (1) UY37847A (es)
WO (2) WO2019034690A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017219204A1 (en) 2016-02-16 2018-08-23 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
MY197636A (en) 2017-01-23 2023-06-29 Genentech Inc Chemical compounds as inhibitors of interleukin-1 activity
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
SG11202001353PA (en) 2017-08-15 2020-03-30 Agios Pharmaceuticals Inc Pyruvate kinase modulators and use thereof
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US20210122739A1 (en) * 2017-08-15 2021-04-29 Inflazome Limited Novel sulfonamide carboxamide compounds
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
MA49901A (fr) * 2017-08-15 2020-06-24 Inflazome Ltd Nouveaux composés de sulfonamide carboxamide
MA49903A (fr) 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
EP3692020A1 (en) 2017-10-03 2020-08-12 Inflazome Limited Novel compounds
EP3707137A1 (en) * 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
KR20200087759A (ko) * 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
SG11202010907VA (en) 2018-05-04 2020-12-30 Inflazome Ltd Novel compounds
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Ｎｌｒｐモジュレータ
CA3104199A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonylurea compounds as inhibitors of interleukin-1 activity
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
MA53221A (fr) 2018-08-15 2022-04-27 Inflazome Ltd Nouveaux composés de sulfonamide urée
JP2022505525A (ja) 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2020254697A1 (en) 2019-06-21 2020-12-24 Ac Immune Sa Fused 1,2 thiazoles and 1,2 thiazines which act as nl3p3 modulators
AU2020314186A1 (en) * 2019-07-17 2022-02-24 Zomagen Biosciences Ltd NLRP3 modulators
WO2021032591A1 (en) 2019-08-16 2021-02-25 Inflazome Limited Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
EP4025565A1 (en) 2019-09-06 2022-07-13 Inflazome Limited Nlrp3 inhibitors
CN117105890A (zh) 2019-11-12 2023-11-24 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
JPWO2021132577A1 (es) * 2019-12-27 2021-07-01
JP2023513935A (ja) 2020-02-18 2023-04-04 インフレイゾーム リミテッド 化合物
CN111217718B (zh) * 2020-03-11 2023-06-16 安徽东健化工科技有限公司 无硫2-溴-4-氟乙酰苯胺合成方法
IL296488A (en) 2020-03-16 2022-11-01 Zomagen Biosciences Ltd nlrp3 modulators
CN111362835B (zh) * 2020-04-20 2022-08-30 苏州科晟通新材料科技有限公司 一种具有阻燃和抗水解功能的碳化二亚胺化合物及其制备方法
CA3181162A1 (en) 2020-06-05 2021-12-09 Stephen W. Kaldor Inhibitors of fibroblast growth factor receptor kinases
CN116075513A (zh) * 2020-06-08 2023-05-05 哈利亚治疗公司 Nek7激酶的抑制剂
KR20230028425A (ko) 2020-06-19 2023-02-28 에이씨 이뮨 에스에이 Nlrp3 인플라마좀 경로를 조절하는 디하이드로옥사졸 및 티오우레아 또는 우레아 유도체
CN112137998A (zh) * 2020-10-10 2020-12-29 上海交通大学医学院附属新华医院 一种活性成分在制备防治坏死性小肠结肠炎药物中的应用
WO2022135567A1 (zh) * 2020-12-25 2022-06-30 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
CN117279903A (zh) 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
AU2022356377A1 (en) * 2021-09-29 2024-04-11 Viva Star Biosciences (Suzhou) Co., Ltd. Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
WO2023116812A1 (zh) * 2021-12-22 2023-06-29 瑞石生物医药有限公司 一种磺酰脲类化合物
WO2023118521A1 (en) 2021-12-22 2023-06-29 Ac Immune Sa Dihydro-oxazol derivative compounds
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US20240034735A1 (en) 2022-07-14 2024-02-01 Ac Immune Sa Novel compounds
US20240101563A1 (en) 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797474A (en) 1955-07-20 1958-07-02 Boehringer & Soehne Gmbh Sulphonylurea derivatives
NL129208C (es) 1965-07-14
BE754588A (fr) 1969-08-07 1971-02-08 Hoechst Ag Thiophene-sulfonyl-urees et les medicaments qui contiennent cessubstances
AU571869B2 (en) 1983-05-09 1988-04-28 E.I. Du Pont De Nemours And Company Pyridyl- and pyrimidyl- sulphonamides
DE3479213D1 (en) 1983-05-16 1989-09-07 Ciba Geigy Ag Herbicidally active and plant growth regulating pyrimidine derivatives, their preparation and use
JPS6045573A (ja) 1983-08-22 1985-03-12 Nissan Chem Ind Ltd ピラゾ−ルスルホニルウレア誘導体，その製法および該誘導体を含有する選択性除草剤
US4723991A (en) 1984-03-23 1988-02-09 E. I. Du Pont De Nemours And Company Lower alkyl 2-[[N-(3-cyano-pyridin-2-yl)aminocarbonyl]aminosulphonyl]benzoate derivatives having herbicidal activity
US4659369A (en) 1984-08-27 1987-04-21 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
AU578307B2 (en) 1984-09-17 1988-10-20 E.I. Du Pont De Nemours And Company Herbicidal pyrazolesulfonamides
FI855180A (fi) 1985-01-18 1986-07-19 Nissan Chemical Ind Ltd Pyrazolsulfonamidderivat, foerfarande foer dess framstaellande och det innehaollande ograesgift.
JPH0720958B2 (ja) 1985-01-18 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホンアミド誘導体、製法および除草剤
CA1231336A (en) 1985-05-30 1988-01-12 George Levitt Herbicidal sulfonamides
JPH0720957B2 (ja) 1985-11-26 1995-03-08 日産化学工業株式会社 ピラゾ−ルスルホニルウレア誘導体、製法および除草剤
JP2570686B2 (ja) 1985-12-23 1997-01-08 日産化学工業株式会社 ピラゾ−ル誘導体
US4830660A (en) 1986-06-19 1989-05-16 Nissan Chemical Industries, Ltd. Imidazolesulfonamide derivatives and herbicides
US4795486A (en) 1986-09-26 1989-01-03 Boehner Beat Aminopyrazinones and aminotriazinones
US4802908A (en) * 1987-01-22 1989-02-07 E. I. Du Pont De Nemours And Company Herbicidal 2-(1H)-pyrazinones
AU7165591A (en) * 1990-01-22 1991-08-05 E.I. Du Pont De Nemours And Company Herbicidal sulfonylureas
ZA915371B (en) 1990-07-17 1993-03-31 Lilly Co Eli Antitumor compositions and methods of treatment
ES2095955T3 (es) 1990-08-29 1997-03-01 Du Pont Pirrolsulfonilureas herbicidas.
DE4039733A1 (de) 1990-12-13 1992-06-17 Basf Ag Substituierte 5-aminopyrazole
CZ36294A3 (en) 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
CA2115990A1 (en) 1991-08-19 1993-03-04 George Albert Boswell Angiotensin ii receptor blocking imidazolinone derivatives
US5169860A (en) 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
JPH06199053A (ja) 1992-12-28 1994-07-19 Sankyo Kagaku Kk 感熱転写記録用色素
JPH06199054A (ja) 1992-12-28 1994-07-19 Dainippon Printing Co Ltd 熱転写シート
JPH06199047A (ja) 1993-01-08 1994-07-19 New Oji Paper Co Ltd 感熱記録体
WO1997011057A1 (en) 1995-09-22 1997-03-27 E.I. Du Pont De Nemours And Company Arthropodicidal 1,4-dihydropyridines and 1,4-dihydropyrimidines
JP3992291B2 (ja) 1995-09-28 2007-10-17 アスビオファーマ株式会社 キナゾリン誘導体
EP0885890A1 (en) 1996-02-26 1998-12-23 Sumitomo Pharmaceuticals Company, Limited Sulfonylureidopyrazole derivatives
SK283679B6 (sk) 1997-01-29 2003-11-04 Pfizer Inc. Deriváty sulfonylmočoviny
SI0964849T1 (en) 1997-01-29 2003-10-31 Pfizer Inc. Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
US6022984A (en) 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
JP2000053649A (ja) 1998-08-11 2000-02-22 Sumitomo Pharmaceut Co Ltd スルホニルウレイドピラゾール誘導体
EP0987552A3 (en) 1998-08-31 2000-06-07 Pfizer Products Inc. Diarylsulfonylurea binding proteins
BR0009042A (pt) 1999-03-15 2001-12-26 Axys Pharm Inc Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
JP2003509378A (ja) * 1999-09-14 2003-03-11 ファイザー・プロダクツ・インク ＩＬ−１ｒａとＩＬ−１プロセシング・放出阻害化合物の併用療法
US6906063B2 (en) 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
WO2001057037A1 (en) 2000-02-04 2001-08-09 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2369967A1 (en) 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
CA2447598A1 (en) 2001-05-18 2002-11-28 Solvay Pharmaceuticals Gmbh Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
FI110677B (fi) 2001-10-12 2003-03-14 Jujo Thermal Oy Lämpöherkkä tallennusmateriaali
EP1441734B1 (en) 2001-10-26 2007-02-28 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
WO2003045400A1 (en) 2001-11-30 2003-06-05 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
WO2003099805A1 (en) 2002-05-28 2003-12-04 3-Dimensional Pharmaceuticals, Inc. Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
US20040092529A1 (en) 2002-10-30 2004-05-13 Pfizer Inc Methods of using piperazine derivatives
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
US7294635B2 (en) 2003-10-03 2007-11-13 Portola Pharmaceuticals, Inc. Substituted isoquinolinones
US7109332B2 (en) 2003-10-03 2006-09-19 Portola Pharmaceuticals, Inc. 2,4-dioxo-3-quinazolinylaryl sulfonylureas
US7205296B2 (en) 2004-09-29 2007-04-17 Portola Pharmaceuticals, Inc. Substituted 2H-1,3-benzoxazin-4(3H)-ones
AR052900A1 (es) 2005-02-11 2007-04-11 Astrazeneca Ab Derivados de tiazol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos para el tratamiento de enfermedades mediadas por ece-1
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
GB0701426D0 (en) 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US8486987B2 (en) 2007-11-16 2013-07-16 University Of Medicine And Dentistry Of New Jersey Mechanism-based small-molecule parasite inhibitors
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
AU2011221849B2 (en) 2010-03-05 2015-04-02 Kyowa Kirin Co., Ltd. Pyrazolopyrimidine derivative
KR20140075698A (ko) * 2011-09-02 2014-06-19 교와 핫꼬 기린 가부시키가이샤 케모카인 수용체 활성 조절제
PL221813B1 (pl) 2013-02-22 2016-05-31 Univ Medyczny W Lublinie Pochodne 1-arylo-6-benzenosulfonyloimidazo[1,2-a][1,3,5] triazyny oraz sposób ich otrzymywania
TW201501713A (zh) 2013-03-01 2015-01-16 Kyowa Hakko Kirin Co Ltd 眼炎症性疾病之預防及／或治療劑
ES2670984T3 (es) 2013-11-05 2018-06-04 Novartis Ag Composiciones y métodos para modular receptores X farnesoides
CN104513239B (zh) 2014-12-10 2017-08-22 沈阳药科大学 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用
TWI698430B (zh) * 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
MA56473A (fr) * 2015-02-16 2022-05-11 The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv Sulfonylurées, composés apparentés, et leur utilisation
US10688077B2 (en) 2015-02-26 2020-06-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
AU2016379454B2 (en) 2015-12-23 2021-01-28 The University Of British Columbia Lipid-linked prodrugs
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
AU2017219204A1 (en) 2016-02-16 2018-08-23 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
EP3445756B1 (en) 2016-04-18 2022-07-06 Novartis AG Compounds and compositions for treating conditions associated with nlrp activity
MA44734A (fr) 2016-04-18 2021-05-19 Novartis Ag Composés et compositions destinés au traitement d'états associés à une activité de nlrp
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
EP3272739A1 (en) 2016-07-20 2018-01-24 NodThera Limited Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
MY197636A (en) * 2017-01-23 2023-06-29 Genentech Inc Chemical compounds as inhibitors of interleukin-1 activity
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
US11236045B2 (en) 2017-06-09 2022-02-01 Cadila Healthcare Limited Substituted sulfoximine compounds
RS62910B1 (sr) 2017-07-07 2022-03-31 Inflazome Ltd Nova jedinjenja sulfonamid karboksamida
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019023145A1 (en) 2017-07-24 2019-01-31 IFM Tre, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
MX2020000911A (es) 2017-07-24 2020-09-10 Novartis Ag Star Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
MA49903A (fr) * 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
US20210122739A1 (en) 2017-08-15 2021-04-29 Inflazome Limited Novel sulfonamide carboxamide compounds
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
EP3668840A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
JP2020531448A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド 新規なスルホンアミドカルボキサミド化合物
MA49901A (fr) * 2017-08-15 2020-06-24 Inflazome Ltd Nouveaux composés de sulfonamide carboxamide
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
EP3692020A1 (en) 2017-10-03 2020-08-12 Inflazome Limited Novel compounds
WO2019079119A1 (en) 2017-10-17 2019-04-25 IFM Tre, Inc. SULFONAMIDES AND ASSOCIATED COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
EP3707137A1 (en) 2017-11-09 2020-09-16 Inflazome Limited Novel sulfonamide carboxamide compounds
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
CN110151749B (zh) 2018-02-13 2022-04-19 中国科学技术大学 冬凌草甲素在制备预防或治疗nlrp3炎症小体相关疾病的药物中的应用
US20200399242A1 (en) 2018-03-02 2020-12-24 Inflazome Limited Novel compounds
US20200407340A1 (en) 2018-03-02 2020-12-31 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166629A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166628A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
SG11202010907VA (en) 2018-05-04 2020-12-30 Inflazome Ltd Novel compounds
WO2020010118A1 (en) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Ｎｌｒｐモジュレータ
CA3104199A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonylurea compounds as inhibitors of interleukin-1 activity
MA53221A (fr) 2018-08-15 2022-04-27 Inflazome Ltd Nouveaux composés de sulfonamide urée
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2022505525A (ja) 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
MX2021005529A (es) 2018-11-13 2021-06-18 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp.
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
CN109432078B (zh) 2018-12-04 2020-09-01 南华大学 一种化合物在制备预防或治疗电离辐射所致认知障碍药物中的应用
GB201905265D0 (en) 2019-04-12 2019-05-29 Inflazome Ltd Inflammasome inhibition
WO2021032591A1 (en) 2019-08-16 2021-02-25 Inflazome Limited Macrocyclic sulfonylurea derivatives useful as nlrp3 inhibitors
TW202115095A (zh) 2019-08-16 2021-04-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
EP4025565A1 (en) 2019-09-06 2022-07-13 Inflazome Limited Nlrp3 inhibitors
JP2023513935A (ja) 2020-02-18 2023-04-04 インフレイゾーム リミテッド 化合物

Also Published As

Publication number Publication date
JP2020531453A (ja) 2020-11-05
WO2020035465A1 (en) 2020-02-20
CL2020000367A1 (es) 2020-08-28
AU2018317798A1 (en) 2020-02-13
MA49903A (fr) 2020-06-24
TW201910316A (zh) 2019-03-16
US11613542B2 (en) 2023-03-28
US20210163412A1 (en) 2021-06-03
EP3668599A1 (en) 2020-06-24
UY37847A (es) 2019-03-29
US20210130359A1 (en) 2021-05-06
CA3071150A1 (en) 2019-02-21
CN111093773A (zh) 2020-05-01
RU2020110219A (ru) 2021-09-17
KR20200041919A (ko) 2020-04-22
IL272557A (en) 2020-03-31
PE20200758A1 (es) 2020-07-27
RU2020110219A3 (es) 2022-02-15
CN112789264A (zh) 2021-05-11
BR112020003014A2 (pt) 2020-07-28
WO2019034690A1 (en) 2019-02-21
EP3837242A1 (en) 2021-06-23
SG11202001166RA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
CR20200588A (es) Compuestos novedosos
MX2020000261A (es) Nuevos compuestos.
PH12021550310A1 (en) Novel sulfonamideurea compounds
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2020001832A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MX2020003383A (es) Compuesto de griseofulvina y uso farmacéutico de este.
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2021007258A (es) Composiciones de esparsentan amorfas.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2019011558A (es) Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).
PH12021550258A1 (en) Cdk8/19 inhibitors